This document is a publication of a European patent application (EP2024001510A1) filed by Fudan University, detailing a method for preparing a HER2 nanobody and its conjugate. The application includes classifications related to antibody preparation, conjugation techniques, and their application in treating cancer (A61P 35/00). The publication date is March 18, 2026.

As this is a patent application publication, it does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in the research, development, and intellectual property protection of antibody-based therapeutics, particularly those targeting HER2 for cancer treatment. Companies operating in this space should be aware of this filing for competitive intelligence and potential licensing or infringement considerations.